Herantis H1'25 preview: Clinical Phase I nearing completion
19 augusti, 08:43
19 augusti, 08:43
Herantis initiated a Phase Ib clinical study in Parkinson's disease with the investigational drug HER-096 in H2 last year. The first results are expected to be completed in the coming weeks, and the full study data will be released by the end of the year.
19 augusti, 08:43
Herantis initiated a Phase Ib clinical study in Parkinson's disease with the investigational drug HER-096 in H2 last year. The first results are expected to be completed in the coming weeks, and the full study data will be released by the end of the year.
Inför Nibes rapport
Analys
Aktierekommendationer
Aktier
Bostadsmarknaden
Selins sorti
Analys
Aktierekommendationer
Aktier
Bostadsmarknaden
Selins sorti
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 646,58